BOOTS COMPANY PLC

1 Thane Road West, Beeston, Nottingham, NG2 3AA
Telephone: +44 (0)1159 595 306
Fax: +44 (0)1159 592 565


Summary of Product Characteristics last updated on the eMC: 07/08/2004
SPC Boots Pain Relief heat Spray


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Pain Relief Warming Spray or Warming Pain Relief Spray or Boots Pain Relief Heat Spray


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredients

 

 

Ethyl nicotinate

1.1% w/w

Methyl salicylate

1.25% w/w

Racemic camphor

0.625% w/w


Go to top of the page
3. PHARMACEUTICAL FORM

Topical spray.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the relief of muscular and rheumatic pains, lumbago, fibrositis, sciatica, sprains, strains and stiffness.

For topical administration.


Go to top of the page
4.2 Posology and method of administration

Adults and children over 5 years: Spray the site of pain using 2 or 3 short bursts, holding the container about 6 inches (15cm) from the skin.

Children under 5 years: Not to be used by children under 5 years.

Elderly: The normal adult dose is still appropriate in the elderly.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any of the ingredients.

Children under 5 years.


Go to top of the page
4.4 Special warnings and precautions for use

For external use only.

Use sparingly as over-application can cause discomfort.

Discontinue use of the product if excessive irritation occurs.

Keep away from the eyes, face, mucous membranes and other sensitive parts of the body.

Do not use on broken or damaged skin or on open cuts.

If symptoms persist, consult your doctor.

Avoid inhalation.

Keep all medicines out of the reach of children.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions known.


Go to top of the page
4.6 Pregnancy and lactation

Although there are no data available to support the use of this product during pregnancy and lactation it is unlikely that use of this product would constitute a hazard to the foetus or breast fed infant.


Go to top of the page
4.7 Effects on ability to drive and use machines

No adverse effect known.


Go to top of the page
4.8 Undesirable effects

Occasional hypersensitivity reactions.


Go to top of the page
4.9 Overdose

It is unlikely that overdosage will occur, but in the event, symptomatic treatment only should be sufficient.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Methyl salicylate has local analgesic and counter irritant properties.

Ethyl nicotinate has vasodilator properties and produces rubefacient activity.

Camphor acts as a mild analgesic, rubefacient and counter irritant.


Go to top of the page
5.2 Pharmacokinetic properties

None stated.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Denatured ethanol

Hydrocarbon 40


Go to top of the page
6.2 Incompatibilities

Not applicable


Go to top of the page
6.3 Shelf life

36 months


Go to top of the page
6.4 Special precautions for storage

Pressurised container:

Protect from sunlight; do not expose to temperatures above 50EC; do not pierce or burn even when empty.


Go to top of the page
6.5 Nature and contents of container

A tinplate internally lacquered aerosol can, having an aervalve and a white/black polypropylene actuator spray fitted with a polyethylene or polypropylene cover.

Pack size: 125ml


Go to top of the page
6.6 Special precautions for disposal and other handling

Do not spray on a naked flame or any incandescent material. Do not use near, and do not place container on, polished or painted surfaces.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

The Boots Company PLC

Nottingham

NG2 3AA


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00014/0275


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

19 July 1982 / 7 December 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

March 2004



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/12688/SPC/


Active Ingredients/Generics

 
   methyl salicylate
   ethyl nicotinate
   racemic camphor